Literatur
- 1
Breedveld F C, Weisman M H, Kavanaugh A F. et al .
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination
therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab
alone in patients with early, aggressive rheumatoid arthritis who had not had previous
methotrexate treatment.
Arthritis Rheum.
2006;
54
26-37
- 2
Cohen S B, Emery P, Greenwald M W. et al .
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy:
Results of a multicenter, randomized, double-blind, placebo-controlled, phase III
trial evaluating primary efficacy and safety at twenty-four weeks.
Arthritis Rheum.
2006;
54
2793-2806
- 3
Dorner T, Kaufmann J, Wegener W A, Teoh N, Goldenberg D M, Burmester G R.
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy
of systemic lupus erythematosus.
Arthritis Res Ther.
2006;
8
R74
- 4
Freim Wahl S G, Folvik M R, Torp S H.
Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission
after treatment with cytostatics and rituximab: case report and review of the literature.
Clin Neuropathol.
2007;
26
68-73
- 5
Genovese M C, Cohen S, Moreland L. et al .
Combination therapy with etanercept and anakinra in the treatment of patients with
rheumatoid arthritis who have been treated unsuccessfully with methotrexate.
Arthritis Rheum.
2004;
50
1412-1419
- 6
Goekoop-Ruiterman Y P, Vries-Bouwstra J K, Allaart C F. et al .
Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial.
Ann Intern Med.
2007;
146
406-415
- 7
Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson S H, Henriksson E W, van Vollenhoven R F.
Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant
proliferative lupus nephritis.
Arthritis Rheum.
2007;
56
1263-1272
- 8
Kappos L, Antel J, Comi G. et al .
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
N Engl J Med.
2006;
355
1124-1140
- 9
Kappos L, Bates D, Hartung H P. et al .
Natalizumab treatment for multiple sclerosis: recommendations for patient selection
and monitoring.
Lancet Neurol.
2007;
6
431-441
- 10
Kremer J M, Genant H K, Moreland L W. et al .
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis:
a randomized trial.
Ann Intern Med.
2006;
144
865-876
- 11
Nishimoto N, Hashimoto J, Miyasaka N. et al .
Study of Active Controlled Monotherapy Used for Rheumatoid Arthritis, an IL-6 inhibitor
(SAMURAI): - Evidence of clinical and radiographic benefit from an X-Ray Reader-Blinded
Randomized Controlled Trial of Tocilizumab.
Ann Rheum Dis.
2007;
, May 7; [Epub ahead of print]
- 12
Schiff M H, Burmester G R, Kent J D. et al .
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing
surveillance of patients with rheumatoid arthritis.
Ann Rheum Dis.
2006;
65
889-894
- 13
Suntharalingam G, Perry M R, Ward S. et al .
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
N Engl J Med.
2006;
355
1018-1028
- 14
Taylor R P, Lindorfer M A.
Drug insight: the mechanism of action of rituximab in autoimmune disease-the immune
complex decoy hypothesis.
Nat Clin Pract Rheumatol.
2007;
3
86-95
- 15
Tokunaga M, Saito K, Kawabata D. et al .
Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving
the central nervous system.
Ann Rheum Dis.
2007;
66
470-475
- 16
Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, Portales-Perez D, Baranda L,
Abud-Mendoza C, Gonzalez-Amaro R.
Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory
to conventional therapy: a pilot study.
Arthritis Res Ther.
2006;
8
R83
- 17
Weinblatt M, Schiff M, Goldman A. et al .
Selective costimulation modulation using abatacept in patients with active rheumatoid
arthritis while receiving etanercept: a randomised clinical trial.
Ann Rheum Dis.
2007;
66
228-234
- 18
Weinblatt M E, Keystone E C, Furst D E, Kavanaugh A F, Chartash E K, Segurado O G.
Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid
arthritis: ARMADA 4 year extended study.
Ann Rheum Dis.
2006;
65
753-759
Prof. Dr. Georg M. N. Behrens
Prof. Dr. Reinhold E. Schmidt
Abteilung Klinische Immunologie und Rheumatologie, Medizinische Hochschule Hannover
Carl-Neuberg-Straße 1
30625 Hannover
Phone: 0511/5325713
Fax: 0511/5325324
Email: behrens.georg@mh-hannover.de
